Russian Drug Capable of Curing COVID-19 in 4 Days Enters Final Trials

A drug, known as Favipiravir, made by a Russian pharmaceutical company, which is said to be potent enough to cure COVID-19, has taken a step closer to its release, after it entered its last phase of testing.

Favipiravir is being tested by Russian pharmaceutical investment firm ChemRar, with the support of the Russian Direct Investment Fund (RDIF).

On Thursday, 22 May, 2020, RDIF announced in a statement that, clinical trials have moved to the final stage in which it is tested on a randomized sample of COVID-19 patients.

The drug has the ability to heal fast and is also available in tablet form.

“We noticed a faster improvement in the general health and clinical condition of the patients taking Favipiravir, which may lead to earlier discharge from hospital and reduce the burden on medical facilities by 30-40 percent in the near future,” said Elena Yakubova, CEO of ChemRar Pharma in a statement.

“Thanks to the administration of Favipiravir, most patients are not infectious as early as the fifth day of treatment, which is critical to stop the epidemic and ensure a swift return to normal life,” Yakubova added.

“We continue to receive promising data during the clinical trials of Favipiravir. At least 85 percent of patients in the control groups completely recovered from coronavirus within 10 days after the start of the treatment with the drug. We expect a positive final result of the trial, which will enable us to complete the registration procedure for the drug in Russia,” RDIF’S CEO Kirill Dmitriev said in the statement.

Categories: News

Leave a Reply